A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Inclusion Criteria:

• Understand and voluntarily sign an informed consent form.

• Age ≥ 18 years at time of signing the informed consent form.

• Able to adhere to the study visit schedule and other protocol requirements

• Participants with multiple myeloma and were enrolled in either THAL-MM-003,CC-5013-MM-009, or CC-5013-MM-010 and discontinued study therapy with thalidomide andhigh-dose dexamethasone or high-dose dexamethasone alone due to: documented disease progression OR inability to tolerate the lowest dosing regimen allowedon previous protocol without a grade 3 or 4 toxicity.

• Eastern Cooperative Oncology Group (ECOG) performance status score 0,1,2

• Recovery from thalidomide or dexamethasone-related toxicity to ≤ grade 2 (NCI CTC)

• Females of child-bearing potential (FCBP) must agree to using two methods ofcontraception

Exclusion Criteria:

• Prior development of a ≥ grade 2 allergic reaction/hypersensitivity or priordevelopment of a grade ≥ 3 rash or desquamation while taking thalidomide NationalCancer Institute Common toxicity Criteria (NCI CTC)

• Use of any standard/experimental anti-myeloma therapy within 28 days of randomizationor use of any experimental non-drug therapy within 56 days of initiation of drugtreatment

• Any serious medical condition, laboratory abnormality, or psychiatric illness thatwill prevent the participant from signing the informed consent form or that will placethe participant at an unacceptable risk for toxicity if he/she participates in thestudy.

• Pregnant or lactating females.

• Prior therapy with CC-5013; prior history of malignancies, other than multiple myeloma (except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of thecervix or breast), unless subject has been free of disease for ≥ 5 years

• More than 4 months has elapsed since the last dose of study drug was administered onstudy Tal MM-003, CC-5013-MM-009, CC-5013-MM-010

• Absolute neutrophil count (ANC) <1,000cells/mm^3 (1.0 X 10^9/L)

• Platelet count <75,000/mm^3 (30 X 10^9/L) for those with <50% if the bone marrownucleated cells re plasma cells; Platelet count <30,000/mm^3 (30 X 10^9/L) for thosewith <50% if the bone marrow nucleated cells re plasma cells

• Serum creatinine >2.5mg/dL; serum SGOT/AST or SGPT/ALT x upper limits of normal (ULN)

• Serum total bilirubin >2.0mg/d/L